trending Market Intelligence /marketintelligence/en/news-insights/trending/aw962yveq6jt3a5nkqqiwg2 content esgSubNav
In This List

Dawnrays Pharmaceutical executive director resigns

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Dawnrays Pharmaceutical executive director resigns

Hong Kong-based Dawnrays Pharmaceutical (Holdings) Ltd. said Li Tung Ming has resigned as an executive director of the company.

Ming also resigned as a board member of Suzhou Dawnrays Pharmaceutical Co. Ltd., Su Zhou Dawnrays Pharmaceutical Science and Technology Co. Ltd., Dawnrays (Nantong) Pharmaceutical Science and Technology Co. Ltd. and Guangdong Dawnrays Pharmaceutical Co. Ltd., which are subsidiaries of Dawnrays.

Ming, who resigned due to health reasons, will remain with the company in an advisory role.

Dawnrays Pharmaceutical is an investment holding company that develops, manufactures, and sells nonpatented pharmaceutical medicines in mainland China and internationally.